What does the current evidence say about GLP-1 drug safety including Ozempic and Wegovy in 2026?
Short answer
In March 2026, the FDA issued a warning letter to Novo Nordisk for failing to report 3 patient deaths on semaglutide (Ozempic/Wegovy), including 1 suicide. Counterfeit semaglutide is circulating in the US market. Meanwhile, peer-reviewed evidence supports GLP-1 efficacy for weight loss (15-20% body weight reduction) and cardiovascular benefit (PMID: 37840095), but long-term safety data beyond 2 years remains limited.
Execution Steps
- 1Search for GLP-1 or semaglutide evidence in LancetClaw.
- 2Review the latest peer-reviewed papers with real PMIDs and citation counts.
- 3Check the safety profile: FDA warnings, reported adverse events, retraction status of cited studies.
- 4Compare evidence across trials: SELECT (PMID: 37840095), STEP trials, SUSTAIN trials.
- 5Get a plain-language summary of the risk-benefit balance for your clinical context.
Prompt Template
What does the latest peer-reviewed evidence say about [semaglutide/GLP-1] safety and efficacy for [weight loss/diabetes/cardiovascular outcomes]?
Common Failure Points
- Relying on manufacturer-funded studies without checking for independent replication
- Ignoring the FDA warning letter about unreported adverse events
- Trusting compounded or online semaglutide products (the FDA warns many contain unverified ingredients)
- Overlooking the limited long-term (>2 year) safety data
FAQ
Composite User Feedback
Medical Student
"The answer pages helped me move from not understanding a paper to knowing which part I should read next."
Clinician
"These guides work because they answer the practical question first, then point me to the workflow I should use."
Medical Librarian
"The strongest pages are the ones that can stand alone as answers and still route people into the right LancetClaw skill."